menu
    • menu
    [{"orgOrder":0,"company":"Parabilis Medicines","sponsor":"RA Capital Management | Fidelity Management & Research Company | Janus Henderson Investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide, Uncojugated","year":"2026","type":"Series F Financing","leadProduct":"Zolucatetide","moa":"CTNNB1 | TCF4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Parabilis Medicines","amount2":0.31,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"Undisclosed","sponsorNew":"Parabilis Medicines \/ RA Capital Management | Fidelity Management & Research Company | Janus Henderson Investors","highestDevelopmentStatusID":"7","companyTruncated":"Parabilis Medicines \/ RA Capital Management | Fidelity Management & Research Company | Janus Henderson Investors"}]

    Find Clinical Drug Pipeline Developments & Deals for Zolucatetide

    Menu

    Zolucatetide

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Parabilis Medicines

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Parabilis Medicines

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zolucatetide,Calcium Folinate,Fluorouracil,Oxaliplatin,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : RA Capital Management | Fidelity Management & Research Company | Janus Henderson Investors

                            Deal Size : $305.0 million

                            Deal Type : Series F Financing

                            DEALS_DEV arrow-down

                            Parabilis Medicines Secures $305M Financing for FOG-001 Clinical Development and Pipeline Advance

                            Details : Series F Financing for Zolucatetide, a peptide targeting CTNNB1 | TCF4, to advance treatment for Desmoid Tumors.

                            Product Name : Undisclosed

                            Product Type : Peptide, Uncojugated

                            Upfront Cash : Undisclosed

                            January 08, 2026

                            Lead Product(s) : Zolucatetide,Calcium Folinate,Fluorouracil,Oxaliplatin,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : RA Capital Management | Fidelity Management & Research Company | Janus Henderson Investors

                            Deal Size : $305.0 million

                            Deal Type : Series F Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.